Trientine Tetrahydrochloride
Trientine tetrahydrochloride (brand name Cuprior) was approved for medical use in the European Union in September 2017. It is indicated for the treatment of Wilson’s disease in adults, adolescents and children five years of age or older who are intolerant to D-penicillamine therapy.
Systematic name
N'-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine;tetrahydrochloride
Brand name(s)
Cuvrior
Therapeutic Category
Treatment of Wilson's disease excluding patients intolerant to penicillamine
Suitable Formulations
Solid